WANY
NAGE

Wealthspire Advisors (New York)’s Niagen Bioscience NAGE Stock Holding History

Wealthspire Advisors (New York)’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,246
Closed -$179K – 714
2020
Q4 		$179K Buy
+37,246
New +$182K 0.01% 559

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Wealthspire Advisors (New York)'s NAGE Position: Q1 2021 in Review

Wealthspire Advisors (New York) sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 37,246 shares — an estimated $179K sold.

Wealthspire Advisors (New York) first reported a position in NAGE in Q4 2020 and held it in 1 quarter. The position peaked at $179K in Q4 2020. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

  • Wealthspire Advisors (New York) reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 37,246 Niagen Bioscience shares in Q1 2021, an estimated $179K.
  • Wealthspire Advisors (New York) first reported a position in Niagen Bioscience in Q4 2020 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Niagen Bioscience position peaked at $179K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2021, filed 17 May 2021.